Skip to content

A study to check the effectiveness and Safety of Turmeric Lemonade energy drink in Patients with moderate knee osteoarthritis.

A Single Center, Randomized, Double blind, Placebo Controlled Pilot Study to Evaluate the Efficacy, Safety and Tolerability of Turmeric Lemonade Energy Drink (Bioactive Curcumin Plus Green Tea Plus Ginger Plus Lemon Plus Lime) manufactured by Golden Tiger Life Corp in the Treatment of Patients with Moderate Osteoarthritis of Knee. - Nil

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076875
Enrollment
27
Registered
2024-11-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: Turmeric Lemonade Energy Drink (Bioactive Curcumin + Green Tea + Ginger + Lemon + Lime): Twice daily for 28 Days, once in the morning and once in the evening approximately at the same t

Sponsors

Golden Tiger Life Corp
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Willing and able to provide voluntary written informed consent and comply with all study procedures. 2. Confirmed diagnosis of unilateral or bilateral knee Osteoarthritis as per clinical American College of Rheumatology (ACR) criteria Clinical OA of the knee is defined as knee pain and at least three out of six of the following criteria: age greater than 50 years, morning stiffness less than 30 min, crepitus, bony tenderness, bony enlargement, and no palpable warmth. 3. Subject with confirmed diagnosis of unilateral or bilateral knee Osteoarthritis for at least greater than 3 months. 4. Subjects with Radio Graphic Evidence of Osteoarthritis, as Determined by Kellgren Lawrence grade III. 5. Subject with index knee joint pain rated less than equal to 44 on a 100 point pain KOOS scale in one or both knees during enrolment. 6. Subject who is able to walk for at least 6 minutes at a moderate to brisk pace. 7. Subjects having mild to moderate pain not adequately or completely controlled with antiinflammatory drugs. 8. Results of screening tests are within normal range or considered not clinically significant by the Investigator. 9. Subject willing to be involved in regular physical activity such as walking, climbing stairs, recording forms, eating, exercise behaviors, etc. 10. Subjects willing to refrain from using ibuprofen, aspirin or other NSAIDs (other than acetaminophen or paracetamol as rescue) and or any other pain reliever including topical application (OTC or prescription), any herbal or Ayurvedic or nutraceutical supplement during the entire trial. 11. Female subjects of childbearing potential must be using a medically acceptable form of birth control. Female subjects of nonchildbearing potential must be amenorrheic for at least 1 year or had a hysterectomy and or bilateral oophorectomy.

Exclusion criteria

Exclusion criteria: 1. Female subjects, who are pregnant, breast feeding or planning to become pregnant. 2. History of allergy or sensitivity to Curcumin, and related compounds or any component of the formulation. 3. History or presence of underlying inflammatory arthropathy, Rheumatoid arthritis (RA), severe OA, gout, Systemic Lupus Erythematosus (SLE) or any other systemic disorder affecting joints. 4. Subject with mild knee Osteoarthritis (Grade I and II) or severe knee Osteoarthritis (Grade IV) as per Kellgren Lawrence Scale. 5. Subject incapacitated or bound to a wheelchair or bed and unable to carry out selfcare activities. 6. Any indication of surgery for OA knee. 7. Subject with a previous history of any knee joint replacement surgery. 8. Recent injury in the area affected by OA of the knee (past 3 months). 9. Have taken any corticosteroid, indomethacin, Glucosamine chondroitin, within 3 months prior to the Treatment Period, Baseline (Visit 1) or intraarticular treatment or injections with corticosteroid or hyaluronic acid or Omega 3 Fatty acids dietary supplements within 6 months preceding the treatment period. 10. Known or clinically suspected infection with Human Immunodeficiency Virus (HIV), hepatitis B or C viruses. 11. Ayurvedic formulation or any form of Complimentary Alternative Medicine (CAM) therapy in the preceding 3 months. 12. Evidence or history of clinically significant (in the judgment of the Investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic diseases, or malignancies. 13. Subject with a history of uncontrolled diabetes. 14. The presence or history of Congestive Cardiac Failure. 15. Subject with history of hypothyroidism and thyroid deficiency except euthyroid. 16. Subject with poorly controlled hypertension (Systolic Blood Pressure greater than equal to 140 mm Hg and Diastolic Blood Pressure greater than equal to 90 mm Hg). 17. Subject who are taking calcium and vitamin D beyond Recommended Dietary Allowance (RDA) levels. 18. History or presence of psychiatric disorder that may impair the ability of Subjects to provide written informed consent. 19. History of high alcohol intake (greater than 2 standard drinks per day) or use of recreational drugs (such as cocaine, methamphetamine, marijuana, etc.). 20. Participation in any other trials involving investigational or marketed products within 30 days prior to the Screening visit. 21. Any condition that in the opinion of the Investigator does not justify the Subjects inclusion in the study.

Design outcomes

Primary

MeasureTime frame
1. Mean Change from Baseline to End of Treatment in Knee injury and osteoarthritis outcome score (KOOS). 2. Change in Endurance from Baseline to End of Treatment assessed by distance covered in 6 minutes walk test.Timepoint: Day 1, Day 14, and Day 28

Secondary

MeasureTime frame
Change from Baseline to End of Treatment in Joint Pain, as determined by Visual Analogue Scale (VAS) Score.Timepoint: Day 1, Day 14, and Day 28;Changes from Baseline to End of Treatment in Complete Metabolic Panel (CMP) blood test and lipid profile.Timepoint: Day 1, Day 14, and Day 28;Change from Baseline to End of Treatment in the requirement of analgesics as a rescue medication (Paracetamol).Timepoint: Day 1, Day 14, and Day 28;Global tolerability assessment by patients and investigators at the end of the treatment on a 3 point scale ranging from good tolerability (side effects may be mild or not observed) to poor tolerability (side effects severe or warranting or needing discontinuation).Timepoint: Day 1, Day 14, and Day 28;Proportion of patients reporting incidences of Adverse Events (AEs) and or Serious Adverse Events (SAEs) during the study.Timepoint: Day 1, Day 14, and Day 28

Countries

India

Contacts

Public ContactMr Pravinkumar Pal

CLINICA Research Solutions LLP

drajay.m@clinicaresearch.com02249705627

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026